Los Angeles, California--(Newsfile Corp. - July 17, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ: APLS) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Apellis and its Syfovre eye medication are the subject of an article published by Investors Business Daily on 7/17 titled, "Apellis Pharma Crashes After Safety Report Undercuts Its Newest Eye Drug." The article states that, "According to a notification posted online by the American Society of Retina Specialists, six patients experienced occlusive retinal vasculitis following their first Syfovre injections. This occurs when the blood vessels become inflamed." Based on this news, shares of Apellis fell by almost 38%.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/173829
